Workforce reduction
Eikon Therapeutics Implements Second Major Staff Reduction in Under Two Years
Eikon Therapeutics; layoffs; biotech; staff cuts; funding cuts; research instrument development; workforce reduction; Roger Perlmutter
Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase
Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment
Carisma Therapeutics to Lay Off Staff, Discontinue CAR-M Programs in Pursuit of Second Candidate
Carisma Therapeutics, Layoffs, Workforce reduction (37%), Dropping clinical CAR-M program, Anti-HER2 CAR-macrophage CT-0508, Anti-mesothelin CAR-monocyte candidate CT-1119, Second candidate focus